Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials.

Background: Shensong Yangxin Capsules (SSYX) is a proprietary Chinese medicine commonly, used in the treatment of arrhythmia. In recent years, a flurry of randomized controlled trials of SSYX was reported in the treatment of Coronary heart disease arrhythmia in China. However, these experiments have not been systematically evaluated by economics. The purpose of this study was to assess the efficacy, safety, and economy of the SSYX in the treatment of arrhythmia in patients with coronary heart disease. Methods: With "Shensong Yangxin Capsules" "Coronary Heart Disease" "Coronary Atherosclerotic Heart Disease"and "Arrhythmia" as the subject words, the relevant journals and conference papers were searched manually in China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP, PubMed, Web Of Science, CBM, Embase and The Cochrane Library. The literature of randomized controlled trials of SSYX in the treatment of coronary heart disease arrhythmia was searched until November 2022. All data were analyzed using RevMan 5.3 Sotware and combined with cost-effectiveness for economic evaluation. Results: Twenty randomized controlled trials were included in this study, with a total of 2011 cases. The meta-analysis showed that the therapeutic effect of SSYX-metoprolol is superior to that of metoprolol alone. SSYX is superior to amiodarone in improving the total clinical effective rate, reducing the incidence of adverse reactions, and reducing the junction premature beats. There was no significant difference between the SSYX and amiodarone in the curative effect of ECG, ventricular premature complexes, and atrial premature beats. The results of pharmacoeconomics show that SSYX has a cost-effectiveness advantage in treating coronary heart disease arrhythmia. Single-factor sensitivity analysis also confirmed the stability of the results. In summary, SSYX has a curative effect, safety, and economy in treating coronary heart disease arrhythmia.

The effects and health risk assessment of cauliflower co-cropping with Sedum alfredii in cadmium contaminated vegetable field.

Phytoremediation coupled with co-cropping is assumed to be good for safety utilization and remediation of heavy metal contaminated farmland, which can ensure farmers' income without increasing health risks for human. In this study, the effects on plant cadmium (Cd) accumulation and health risk of consuming the vegetable plant were compared between monoculture and co-cropping of cauliflower (Brassica oleracea) with two ecotypes of Sedum alfredii in a moderately (0.82 mg kg-1) Cd contaminated greenhouse vegetable field. The results showed that co-cropping with S. alfredii raised Cd concentration in edible part of cauliflower with slightly growth promotion. The health risk of consuming cauliflower to different groups of people have been evaluated by calculating Hazard Quotient (HQ) and all HQ value were less than 1.0, which indicated that eating co-cropped cauliflower would not cause health risks to adults and children. Besides, the Cd concentration of hyperaccumulating ecotype (HE) of S. alfredii was 27.3 mg kg-1 in monoculture and it increased to 51.2 mg kg-1 after co-cropping with cauliflower, suggesting that the co-cropping system promoted HE Cd absorption capacity. Therefore, the "Phytoextraction Coupled with Agro-safe-production" (PCA) model of cauliflower and HE can serve as an alternative sustainable strategy in the Cd moderate polluted greenhouse.